A phase II trial of VP 16–213 in adults with refractory acute myeloid leukemia
- 1 October 1984
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 7 (5) , 471-474
- https://doi.org/10.1097/00000421-198410000-00015
Abstract
VP-16-213 [etoposide] was studied in 38 adult patients with relapsed or refractory acute myeloid leukemia as part of a randomized trial in an ECOG [Eastern Cooperative Oncology Group] master protocol. In this group of heavily pretreated patients, an overall response rate of 18% was achieved (5% CR [complete remission], 13% PR [partial remission]). Toxicity was mild and aplasia was rarely observed. Responses were seen in all of the FAB [French-American-British] myeloid subtypes. Patients who had never achieved remission status responded as well as patients who had relapsed.This publication has 0 references indexed in Scilit: